Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Two studies have identified variants of UNC93B1 that are associated with enhanced TLR7 and TLR8 activity and the development of systemic lupus erythematosus.
Integrins are involved in joint tissue development and homeostasis, and perturbations in the availability of integrin ligands or in downstream integrin signalling are linked to the pathogenesis of osteoarthritis (OA). This Review discusses current evidence and future perspectives for therapeutically targeting integrins in OA.
Genetic, epigenetic and transcriptomic studies in hyperuricaemia and gout have, in the past 6 years, provided important insights into the underlying molecular mechanisms, revealing new inflammatory pathways and epigenetic factors and expanding research beyond European populations.
Treatment with the endogenous metabolite itaconate induced phenotypic and metabolic changes in fibroblast-like synoviocytes and reduced the severity of arthritis in an animal model.
Sjögren syndrome is a chronic autoimmune disease affecting exocrine glands, causing dryness and systemic symptoms. Treatment has been primarily symptomatic, but advances in our understanding of its pathophysiology offer promise for targeted therapies, aiming for personalized care and improved outcomes.
New findings identify HSP60 and other synovial stromal-derived autoantigens as targets for pathogenic autoantibodies, exacerbating arthritis and serving as potential biomarkers.
Type 2 innate lymphoid cells protect against kidney inflammation in lupus nephritis, and enhancing their adhesion via integrin α4β7 upregulation, particularly through IL-33 treatment, could be a promising therapeutic approach.
This Review outlines the role of platelets in Kawasaki disease and the immune-effector role of platelets in amplifying inflammation related to Kawasaki disease vasculitis and highlights therapeutic strategies that target platelets or platelet-derived molecules.
The bispecific T cell engager (BiTE) blinatumomab showed promising clinical efficacy in a pilot study of six patients with multidrug-resistant rheumatoid arthritis.
Joint lubrication is important for minimizing friction between articulating joint surfaces and for preventing cartilage wear that can otherwise exacerbate osteoarthritis. This Review examines the advantages and disadvantages of various strategies for restoring normal joint lubrication.
In this Review, the authors provide an overview of the immunological, clinical and pathophysiological features of anti-citrullinated protein antibodies in rheumatoid arthritis, highlighting the latest findings regarding the complex contribution of anti-citrullinated protein antibodies to the disease.
A wearable smart device that uses reconfigurable electronics and conductive polymer-based microneedles was able to monitor inflammation and provide transdermal drug delivery and electrical stimulation in a rat model of arthritis.
Researchers have introduced the term ‘MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic’ (MIP-C) to describe cases of MDA5 autoimmunity that surged during the COVID-19 pandemic.
New research provides a potential explanation for why long-term sclerostin neutralization leads to continued bone mass gain, despite attenuation of its short-term effects on bone formation.
In this Review, the authors argue that the risk of osteoporosis in patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) is multifactorial, with contributions from iRMD-specific factors, comorbidities, general risk factors and the effects of iRMD therapies such as glucocorticoids.
As the pace of genetic discovery has accelerated, so too has the need for clinicians and researchers to acknowledge and understand the impact of language in scientific publications. The use of inaccurate language contributes to systemic bias and eugenic ideologies that remain pervasive in biomedical science, including in rheumatology.
Guidelines for the management of psoriatic arthritis (PsA) need to undergo revision to take on board new evidence, particularly in relation to therapeutics. In March 2024, EULAR published updated recommendations for the pharmacological treatment of PsA, and an expert group published consensus statements intended to complement existing guidelines.
